TY - JOUR
T1 - Delta-like ligand 4-notch signaling in macrophage activation
AU - Nakano, Toshiaki
AU - Fukuda, Daiju
AU - Koga, Jun Ichiro
AU - Aikawa, Masanori
N1 - Funding Information:
The preparation of this article and the experimental data described here were supported by the National Institutes of Health grants R01HL66086, R01HL107550, and R01HL126901 and the American Heart Association Grant-In-Aid to Dr Aikawa; the postdoctoral fellowship awards from the Japanese Heart Foundation/Bayer Japan, the Japan Society for the Promotion of Science, and the Uehara Memorial Foundation to Dr Fukuda; the Banyu Fellowship Program from the Banyu Life Science Foundation International to Dr Koga; and the American Heart Association Postdoctoral Fellowship and the International Research Fund for Subsidy of Kyushu University School of Medicine Alumni to Dr Nakano.
Publisher Copyright:
© 2016 American Heart Association, Inc.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - The Notch signaling pathway regulates the development of various cell types and organs, and also contributes to disease mechanisms in adults. Accumulating evidence suggests its role in cardiovascular and metabolic diseases. Notch signaling components also control the phenotype of immune cells. Delta-like ligand 4 (Dll4) of the Notch pathway promotes proinflammatory activation of macrophages in vitro and in vivo. Dll4 blockade attenuates chronic atherosclerosis, vein graft disease, vascular calcification, insulin resistance, and fatty liver in mice. The Dll4-Notch axis may, thus, participate in the shared mechanisms for cardiometabolic disorders, serving as a potential therapeutic target for ameliorating these global health problems.
AB - The Notch signaling pathway regulates the development of various cell types and organs, and also contributes to disease mechanisms in adults. Accumulating evidence suggests its role in cardiovascular and metabolic diseases. Notch signaling components also control the phenotype of immune cells. Delta-like ligand 4 (Dll4) of the Notch pathway promotes proinflammatory activation of macrophages in vitro and in vivo. Dll4 blockade attenuates chronic atherosclerosis, vein graft disease, vascular calcification, insulin resistance, and fatty liver in mice. The Dll4-Notch axis may, thus, participate in the shared mechanisms for cardiometabolic disorders, serving as a potential therapeutic target for ameliorating these global health problems.
UR - http://www.scopus.com/inward/record.url?scp=84983748408&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983748408&partnerID=8YFLogxK
U2 - 10.1161/ATVBAHA.116.306926
DO - 10.1161/ATVBAHA.116.306926
M3 - Review article
C2 - 27562914
AN - SCOPUS:84983748408
SN - 1079-5642
VL - 36
SP - 2038
EP - 2047
JO - Arteriosclerosis, Thrombosis, and Vascular Biology
JF - Arteriosclerosis, Thrombosis, and Vascular Biology
IS - 10
ER -